Search results
Showing 136 to 150 of 1300 results for heart OR cardi* OR arrythmia
This indicator covers the proportion of patients with ST-segment elevation myocardial infarction (STEMI) who had balloon inflation for primary percutaneous coronary intervention (PCI) in less than 60 minutes from time of admission at a centre with primary PCI facilities. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG92
This indicator covers the percentage of patients with a new diagnosis of hypertension in the preceding 1 April to 31 March who have a record of a 12-lead ECG performed in the 3 months before or after the date of entry to the hypertension register. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM77
Myocardial infarction: medication for MI more than 12 months ago (IND126)
This indicator covers the percentage of patients with a history of myocardial infarction (more than 12 months ago) who are currently being treated with an ACE-I (or ARB if ACE-I intolerant), aspirin (or clopidogrel, or anticoagulant drug therapy) and a statin, and a beta-blocker for those patients with left ventricular systolic dysfunction. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM80
Leadless cardiac pacemaker implantation for bradyarrhythmias (IPG626)
Evidence-based recommendations on leadless cardiac pacemaker implantation for bradyarrhythmias in adults. This involves inserting a device into the heart that helps it beat at a normal rate.
View recommendations for IPG626Show all sections
Implanting a baroreceptor stimulation device for resistant hypertension
In development Reference number: GID-IP1180 Expected publication date: TBC
Evidence-based recommendations on VA ECMO for extracorporeal cardiopulmonary resuscitation (ECPR) in adults with refractory cardiac arrest. This involves using an artificial lung to oxygenate the blood outside the body.
View recommendations for IPG808Show all sections
Question Intra-aortic balloon counter‑pulsation: In people with acute heart failure and hypoperfusion syndrome, is the use of...
Omecamtiv mecarbil for treating chronic heart failure with reduced ejection fraction [ID3912]
Awaiting development Reference number: GID-TA10797 Expected publication date: TBC
This quality standard covers managing hypertension in adults. It includes diagnosis and investigations, treatment and specialist referral. It describes high-quality care in priority areas for improvement.
View quality statements for QS28Show all sections
Sections for QS28
- Quality statements
- Quality statement 1: Diagnosis – ambulatory blood pressure monitoring
- Quality statement 2: Investigations for target organ damage
- Quality statement 3: Statin therapy
- Quality statement 4: Blood pressure targets
- Quality statement 5: Review of cardiovascular disease risk factors
- Quality statement 6: Referral to a specialist for adults with resistant hypertension
- Update information
Resources, case studies and patient decision aids to show how you can use evidence to improve care and services
Evidence-based recommendations on rivaroxaban (Xarelto) for preventing atherothrombotic events in adults with coronary or peripheral artery disease.
managing fluid overload in people with advanced heart failure in the community:- In people with advanced heart failure and...
Evidence-based recommendations on subcutaneous implantable cardioverter defibrillator insertion for preventing sudden cardiac death. This involves placing a device under the skin of the chest, which detects and treats fast heartbeats called tachyarrhythmias.
This guideline covers diagnosing, assessing, and treating community-acquired and hospital-acquired pneumonia, including bacterial pneumonia secondary to COVID-19, in babies over 1 month (corrected gestational age), children, young people and adults. It aims to optimise antibiotic use and reduce antibiotic resistance.